Management of triple-negative breast cancer by natural compounds through different mechanistic pathways

Area of Science:

• Oncology
• Epigenetics
• Genetics

Background:

• Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype.
• TNBC is defined by the absence of estrogen, progesterone, and HER2 receptors, leading to poor prognosis.
• Genetic and epigenetic alterations are primary drivers of TNBC development, progression, and metastasis.

Purpose of the Study:

• To comprehensively review TNBC subtypes and their associated epigenetic causes.
• To elucidate the genetic landscape of TNBC, including key genes and signaling pathways.
• To explore the therapeutic potential of natural compounds in TNBC management.

Main Methods:

• Literature review of TNBC subtypes, focusing on epigenetic mechanisms like DNA methylation and histone modification.
• Compilation of genetic associations, including significant genes and signaling pathways implicated in TNBC progression.
• Analysis of research on natural compounds and their mechanistic pathways for TNBC treatment.

Main Results:

• Detailed classification of TNBC subtypes and their specific epigenetic drivers.
• Comprehensive mapping of genetic factors and signaling pathways contributing to TNBC.
• Identification of various natural compounds and their potential therapeutic roles in TNBC.

Conclusions:

• Epigenetic dysregulation is central to TNBC pathogenesis and metastasis.
• Understanding the genetic basis of TNBC is crucial for targeted therapies.
• Natural compounds offer promising avenues for novel TNBC treatment strategies.